ReviewTherapeutics and clinical risk management2019
Emerging Treatment Options For Cancer-Associated Cachexia: A Literature Review.
Review in Therapeutics and clinical risk management, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- The barriers to interprofessional care for cancer cachexia among Japanese healthcare providers: A nationwide survey.Journal of cachexia, sarcopenia and muscle · 2024Article
- Relationship between Survival Days, Cancer Cachexia, and Activities of Daily Living in Palliative Cancer Patients Undergoing Rehabilitation.Progress in rehabilitation medicine · 2024Article
- Lysine methylation signaling in skeletal muscle biology: from myogenesis to clinical insights.The Biochemical journal · 2023Review
- Cancer-cell-secreted extracellular vesicles target p53 to impair mitochondrial function in muscle.EMBO reports · 2023Article
- Measuring What Is Meaningful in Cancer Cachexia Clinical Trials: A Path Forward With Digital Measures of Real-World Physical Behavior.JCO clinical cancer informatics · 2023Review
- Article
- Targeting Gut Microbiota in Cancer Cachexia: Towards New Treatment Options.International journal of molecular sciences · 2023Review
- A Pre-Clinical Study of Sub-Anesthetic Ketamine as Remedy in 5-Fluorouracil-Induced Cachexia Model.Life (Basel, Switzerland) · 2022Article
- Pathophysiology of cachexia and characteristics of dysphagia in chronic diseases.Asia-Pacific journal of oncology nursing · 2022Review
- Kampo medicines for supportive care of patients with cancer: A brief review.Integrative medicine research · 2022Review
- Altered Plasma Fatty Acid Abundance Is Associated with Cachexia in Treatment-Naïve Pancreatic Cancer.Cells · 2022Article
- Impact ofFrontiers in oncology · 2021Article
- Novel Nutrition-Based Nomograms to Assess the Outcomes of Lung Cancer Patients Treated With Anlotinib or Apatinib.Frontiers in oncology · 2021Article
- Withaferin A and Ovarian Cancer Antagonistically Regulate Skeletal Muscle Mass.Frontiers in cell and developmental biology · 2021Article
- Cachexia: Pathophysiology and Ghrelin Liposomes for Nose-to-Brain Delivery.International journal of molecular sciences · 2020Review
- Mathematical Model of Muscle Wasting in Cancer Cachexia.Journal of clinical medicine · 2020Article
- Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC.JTO clinical and research reports · 2020Article
- Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome.ESMO open · 2020Article
- Development and Validation of a Nomogram for Predicting Survival in Gallbladder Cancer Patients With Recurrence After Surgery.Frontiers in oncology · 2020Article
- Dietary restriction of amino acids for Cancer therapy.Nutrition & metabolism · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cachexia is a disease that has been recognized since antiquity; however, research in this area has recently increased. Promising new agents, including anamorelin hydrochloride, have been tested in large randomized controlled studies, and multidrug as well as multimodal approaches have been proposed as having the potential to improve outcomes in patients with cancer cachexia. However, standard treatment remains elusive. This review summarizes the current literature on treatment of cancer-associated cachexia, showing that there are challenges associated with conducting clinical trials in such patients. First, poor recruitment, retention, and compliance among cachectic patients cause research delays. Second, the lack of consensus regarding clinically meaningful endpoints impedes standardization of study designs and results. Further consideration is needed to identify the most suitable study design and endpoints, which can lead to the development of pharmacological and nonpharmacological interventions that improve patients' prognosis and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.